Trial Profile
Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FEVEX
- Sponsors Oncotech
- 14 Jun 2016 Status changed from not yet recruiting to recruiting.
- 08 Apr 2015 New trial record